Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06831461 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Proton Versus Photon Radiotherapy in Adults With Primary Brain Tumors

Study acronym: PRIDE
StatusRecruiting
PhaseNot applicable
Started2025-07-01
View on ClinicalTrials.gov ↗

Amendment history

2025-09-15
notable
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v2
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2025-07-31→confirmed 2025-07-01
Study sitesdetails revised at 1 of 1 site
2025-06-04
minor
Study Identification, Study Status, Oversight v1
Start date2025-04-01→2025-07-31
Study titlerevised
Proton Versus Photon Radiotherapy in Adults withWith Primary Brain Tumors
2025-02-12
minor
Original filing
666 trials monitored
See 38 trials at risk
This study will be done in adults with brain tumors having good prognosis requiring treatment with radiotherapy. The current practice for brain radiotherapy involves treatment using X rays (photon radiotherapy). Proton beam therapy is a more advanced form of delivering radiation, which allows the reduction of the dose of radiation to the parts of the brain surrounding the tumor. After treatment with photon radiotherapy, certain late effects of radiation, like memory decline, hormonal deficits, hearing loss, and worsening of neurological function, can occur in some patients. From the evaluation of dose profiling, proton beam therapy has the potential to reduce the possibility of side effects by reducing the dose to critical organs. However, there is no clinical data to demonstrate whether the theoretical dose reduction translates to a clinically meaningful benefit. In the proposed study, 156 patients will be randomly allocated to either proton or photon radiotherapy in 1: 1 ratio. The primary objective of the study is to explore whether proton therapy improves functional survival, which is life expectancy without recurrence, death, or complications from radiotherapy.
Trial Details
NCT Number NCT06831461
Lead Sponsor Tata Memorial Centre
Conditions Primary Brain Tumors, Diffuse Glioma, Meningioma, Pituitary Adenoma, Low Grade CNS Tumors
Enrollment 156 participants
Start Date 2025-07-01
Primary Completion 2032-12-31 (estimated)
Study Completion 2032-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-09-16